bi 730357
Small moleculeexperimental
Clinical trial activity
13 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 12, 2017 (NCT03004404)
Timeline
Indications
Mechanism of action
- Nuclear receptor ROR-gammaANTAGONIST
RORC antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bi 730357
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04680676 | Phase 2 | May 2, 2022 | Boehringer Ingelheim |
| NCT04679948 | Phase 1 | Dec 21, 2020 | Boehringer Ingelheim |
| NCT04590937 | Phase 1 | Oct 20, 2020 | Boehringer Ingelheim |
| NCT04147260 | Phase 1 | Nov 6, 2019 | Boehringer Ingelheim |
| NCT03886272 | Phase 1 | Apr 11, 2019 | Boehringer Ingelheim |
| NCT03835481 | Phase 2 | Mar 18, 2019 | Boehringer Ingelheim |
| NCT03804671 | Phase 1 | Jan 31, 2019 | Boehringer Ingelheim |
| NCT03793621 | Phase 1 | Jan 21, 2019 | Boehringer Ingelheim |
| NCT03782987 | Phase 1 | Jan 10, 2019 | Boehringer Ingelheim |
| NCT03635099 | Phase 2 | Sep 17, 2018 | Boehringer Ingelheim |
| NCT03664011 | Phase 1 | Sep 10, 2018 | Boehringer Ingelheim |
| NCT03279978 | Phase 1 | Jan 9, 2018 | Boehringer Ingelheim |
| NCT03004404 | Phase 1 | Jan 12, 2017 | Boehringer Ingelheim |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 13 | 13 | 2 | 2017 |
1 organizations
Page 1 / 1